Markets SVB Leerink slashes Genfit PT to $20 from $50 SVB Leerink slashed its price target for Genfit (NASDAQ:GNFT) to $20 from $50, but maintained its “outperform” rating, citing topline interim Phase 3 results that showed elafibranor failed to demonstrate a statistically... May 12, 2020